Minodronate for the treatment of osteoporosis

References

• KanisJAMcCloskeyEVJohanssonHEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporos Int2013241235723079689
   PubMed Web of Science ®Google Scholar
• YoshimuraNMurakiSOkaHPrevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability studyJ Bone Miner Metab200927562062819568689
   PubMed Web of Science ®Google Scholar
• KwokAWLeungJCChanAYPrevalence of vertebral fracture in Asian men and women: comparison between Hong Kong, Thailand, Indonesia and JapanPublic Health2012126652353122560410
   PubMed Web of Science ®Google Scholar
• BallaneGCauleyJALuckeyMMEl-Hajj FuleihanGWorldwide prevalence and incidence of osteoporotic vertebral fracturesOsteoporos Int20172851531154228168409
   PubMed Web of Science ®Google Scholar
• KeeneGSParkerMJPryorGAMortality and morbidity after hip fracturesBMJ19933076914124812508166806
   PubMed Web of Science ®Google Scholar
• CummingRGKlinebergRKatelarisACohort study of risk of institutionalization after hip fracturesAust N Z J Public Health19962065795829117962
   PubMed Web of Science ®Google Scholar
• HoltGSmithRDuncanKHutchisonJDGregoriAReidDOutcome after sequential hip fracture in the elderlyJ Bone Joint Surg Am201294191801180823032591
   PubMed Web of Science ®Google Scholar
• HaginoHEndoNHaradaASurvey of hip fractures in Japan: recent trends in prevalence and treatmentJ Orthop Sci201722590991428728988
   PubMed Web of Science ®Google Scholar
• BallaneGCauleyJALuckeyMMFuleihanGel-HSecular trends in hip fractures worldwide: opposing trends East versus WestJ Bone Miner Res20142981745175524644018
   PubMed Web of Science ®Google Scholar
• FisherAAO’BrienEDDavisMWTrends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapyBone200945224625319409518
   PubMed Web of Science ®Google Scholar
• AlvesSMEconomouTOliveiraCOsteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective studyBone201353243043623274347
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research GroupJ Clin Endocrinol Metab200085114118412411095442
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• ScottiLArféAZambonAMerlinoLCorraoGCost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilization databasesBMJ Open201443e003758
   Web of Science ®Google Scholar
• MoriwakiKMouriMHaginoHCost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in JapanOsteoporos Int20172861939195028265718
   PubMed Web of Science ®Google Scholar
• ChataniYMinodronic acid hydrate as a new therapeutic agent for osteoporosisClin Calcium2005151914 Japanese15632466
   PubMedGoogle Scholar
• KuboTShimoseSMatsuoTFujimoriJOchiMMinodronate for the treatment of osteoporosisDrugs Today (Barc)20104613337
   Web of Science ®Google Scholar
• TanishimaSMorioYA review of minodronic acid hydrate for the treatment of osteoporosisClin Interv Aging2013818518923440003
   PubMed Web of Science ®Google Scholar
• RodanGAFleischHABisphosphonates: mechanism of actionJ Clin Invest19969712269226968675678
   PubMed Web of Science ®Google Scholar
• LuckmanSPHughesDECoxonFPGrahamRRussellGRogersMJNitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding protein, including RasJ Bone Miner Res19981345815899556058
   PubMed Web of Science ®Google Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonateJ Pharmacol Exp Ther2001296223524211160603
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• RussellRGGWattsNBEbetinoFHRogersMJMechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporos Int200819673375918214569
   PubMed Web of Science ®Google Scholar
• EbetinoFHHoganAMSunSThe relationship between the chemistry and biological activity of the bisphosphonatesBone2011491203321497677
   PubMed Web of Science ®Google Scholar
• TurekJEbetinoFHLundyMWBisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbitsCalcif Tissue Int201290320221022249525
   PubMed Web of Science ®Google Scholar
• HaginoHNishizawaYSoneTA double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosisBone20094461078108419264155
   PubMed Web of Science ®Google Scholar
• MatsumotoTHaginoHShirakiMEffect on daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind studyOsteoporos Int20092081429143719101754
   PubMed Web of Science ®Google Scholar
• OkazakiRHaginoHItoMEfficacy and safety of monthly oral minodronate in patients with involutional osteoporosisOsteoporos Int20122361737174521932114
   PubMed Web of Science ®Google Scholar
• HaginoHShirakiMFukunagaMThree years of treatment with minodronate in patients with postmenopausal osteoporosisJ Bone Miner Metab201230443944622134624
   PubMed Web of Science ®Google Scholar
• HaginoHShirakiMFukunagaMNumber and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trialJ Bone Miner Metab201331554455023529800
   PubMed Web of Science ®Google Scholar
• EbinaKNoguchiTHiraoMKaneshiroSTsukamotoYYoshikawaHComparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosisJ Bone Miner Metab201634324325026303222
   PubMed Web of Science ®Google Scholar
• KamimuraMUchiyamaSNakamuraYIkegamiSMukaiyamaKKatoHShort-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markersTher Clin Risk Manag20171316116828243105
   PubMed Web of Science ®Google Scholar
• TanakaSYoshidaAKonoSItoMEffectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: an open-label, randomized, parallel-group studyJ Orthop Sci201722353654128108224
   PubMed Web of Science ®Google Scholar
• EbinaKNoguchiTHiraoMEffects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective studyOsteoporos Int201627135135926475289
   PubMed Web of Science ®Google Scholar
• SakaiAIkedaSOkimotoNClinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonate: the BP-MUSASHI studyOsteoporos Int20142592245225324899103
   PubMed Web of Science ®Google Scholar
• OhishiTFujitaTSuzukiDChanges of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patientsEndocr Res201742323224028318330
   PubMed Web of Science ®Google Scholar
• TodaASawadaKYoshimuraAEffects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifeneInt J Womens Health2017982182529180905
   PubMed Web of Science ®Google Scholar
• NakatohSEffect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitolJ Bone Miner Metab201836222122828293779
   PubMed Web of Science ®Google Scholar
• OhishiTFujitaTSuzukiDInitiation of monthly minodronate therapy at an early stage after hip fractureJ Clin Densitom201619335235827067298
   PubMed Web of Science ®Google Scholar
• IwamotoJOkanoHFuruyaTPatient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodronate Alendronate/Risedronate Trial in Osteoporosis (MARTO)J Bone Miner Metab201634220120825794468
   PubMed Web of Science ®Google Scholar
• YoshiokaTOkimotoNOkamotoKSakaiAA comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patientsJ Bone Miner Metab201331215316023076293
   PubMed Web of Science ®Google Scholar
• FujimotoKInageKOritaSThe nature of osteoporotic back pain without acute vertebral fracture: a prospective multicenter study on the analgesic effect of monthly minodronic acid hydrateJ Orthop Sci201722461361728284540
   PubMed Web of Science ®Google Scholar
• NakamuraMUmetsuRAbeJAnalysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug eventsJ Pharm Health Care Sci201513426819745
   PubMedGoogle Scholar
• MillerPDThe kidney and bisphosphonatesBone2011491778121232648
   PubMed Web of Science ®Google Scholar
• KomadaTMorishitaYKitamuraMAcute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate)Intern Med201352121383138723774552
   PubMed Web of Science ®Google Scholar
• MashibaTTurnerCHHiraoTEffects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fracturesBone200129327127811557372
   PubMed Web of Science ®Google Scholar
• KomatsubaraSMoriSMashibaTSuppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog ribJ Bone Miner Res2004196999100515125797
   PubMed Web of Science ®Google Scholar
• BalaYFarlayDChapurlatRDBoivinGModifications of bone material properties in postmenopausal osteoporotic women long-term treated with alendronateEur J Endocrinol2011165464765521821631
   PubMed Web of Science ®Google Scholar
• JinACobbJHansenUThe effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack densityBone Joint Res201761060260929066534
   PubMed Web of Science ®Google Scholar
• MaSGohELJinALong-term effects of bisphosphonate therapy: perforations, microcracks and mechanical propertiesSci Rep201774339928262693
   PubMed Web of Science ®Google Scholar
• KimotoATanakaMNozakiKIntermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatmentBone201355118919723486179
   PubMed Web of Science ®Google Scholar
• NagiraKHaginoHKameyamaYTeshimaREffects of minodronate on cortical bone response to mechanical loading in ratsBone201353127728323207800
   PubMed Web of Science ®Google Scholar
• YamagamiYMashibaTIwataKTanakaMNozakiKYamamotoTEffects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeysBone20135411723356990
   PubMed Web of Science ®Google Scholar
• TanakaMMoriHKayasugaREffect of intermittent and daily regimens of minodronic acid on bone metabolism in an ovariectomized rat model of osteoporosisCalcif Tissue Int201495216617324903232
   PubMed Web of Science ®Google Scholar
• ItoMSoneTFukunagaMEffect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosisJ Bone Miner Metab201028333434119937358
   PubMed Web of Science ®Google Scholar
• MiyaokaDImanishiYOharaMEffects of teriparatide and sequential minodronate on lumbar spine bone mineral density and microarchitecture in osteoporosisCalcif Tissue Int2017101439640328589205
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• SandersonJMartyn-St JamesMStevensJClinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysisBone201689525827262775
   PubMed Web of Science ®Google Scholar
• ZhouJMaXWangTZhaiSComparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analysesOsteoporos Int201627113289330027273112
   PubMed Web of Science ®Google Scholar
• QassemAForcieaMAMcLeanRMDenbergTDClinical Guidelines Committee of the American College of PhysiciansTreatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of PhysiciansAnn Intern Med20171661181883928492856
   PubMed Web of Science ®Google Scholar
• CottéFEFardellonePMercierFGaudinAFRouxCAdherence to monthly and weekly oral bisphosphonates in women with osteoporosisOsteoporos Int201021114515519459025
   PubMed Web of Science ®Google Scholar
• ConfavreuxCBCanoui-PoitrineFSchottAMAmbrosiVTainturierVChapurlatRDPersistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance databaseEur J Endocrinol2012166473574122258112
   PubMed Web of Science ®Google Scholar
• PannemanMJLipsPSenSSHeringsRMUndertreatment with anti-osteoporotic drugs after hospitalization for fractureOsteoporos Int200415212012414618302
   PubMed Web of Science ®Google Scholar
• CadaretteSMKatzJNBrookhartMATrends in drug prescribing for osteoporosis after hip fracture, 1995–2004J Rheumatol200835231932618061977
   PubMed Web of Science ®Google Scholar
• RabendaVVanoverloopJFabriVLow incidence of anti-osteoporosis treatment after hip fractureJ Bone Joint Surg Am200890102142214818829912
   PubMed Web of Science ®Google Scholar
• WilkASajjanSModiAFanCPMavrosPPost-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USAOsteoporos Int201425122777278625112720
   PubMed Web of Science ®Google Scholar
• LylesKWColón-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• OsakiMTatsukiKHashikawaTBeneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese womenOsteoporos Int201223269570321394496
   PubMed Web of Science ®Google Scholar
• BoneHGHoskingDDevogelaerJPTen years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med2004350121189119915028823
   PubMed Web of Science ®Google Scholar
• MellströmDDSörensenOHGoemaereSRouxCJohnsonTDChinesAASeven years of treatment with risedronate in women with postmenopausal osteoporosisCalcif Tissue Int200475646246815455188
   PubMed Web of Science ®Google Scholar
• BlackDMReidIRCauleyJAThe effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)J Bone Miner Res201530593494425545380
   PubMed Web of Science ®Google Scholar
• NevittMCThompsonDEBlackDMEffect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research GroupArch Intern Med20001601778510632308
   PubMedGoogle Scholar
• KushidaKFukunagaMKishimotoHA comparison of incidence of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trialJ Bone Miner Metab200422546947815316868
   PubMed Web of Science ®Google Scholar
• GuiQXuCLiDZhuangLXiaSYuSUrinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in an rat model of bone metastasesMol Med Rep20151234243424926081451
   PubMed Web of Science ®Google Scholar
• IwamotoJTakedaTIchimuraSUzawaMComparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fracturesKeio J Med200352423023514748475
   PubMedGoogle Scholar
• FulfaroFCasuccioATicozziCRipamontiCThe role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trialsPain19987831571699870569
   PubMed Web of Science ®Google Scholar
• BonabelloAGalmozziMRBruzzeseTZeraGPAnalgesic effect of bisphosphonates in micePain200191326927511275384
   PubMed Web of Science ®Google Scholar
• KakimotoSNagakuraYTamuraSMinodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain modelsEur J Pharmacol20085891–39810118565509
   PubMed Web of Science ®Google Scholar
• KhanAAMorrisonAHanleyDADiagnosis and management of osteonecrosis of the jaw: a systematic review and international consensusJ Bone Miner Res201530132325414052
   PubMed Web of Science ®Google Scholar
• AdlerRAEl-Hajj FuleihanGBauerDCManaging osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2016311163526350171
   PubMed Web of Science ®Google Scholar
• RuggieroLSDodsonTBAssaelLAAmerican Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of jaw – 2009 updateAust Endod J200935311913019961450
   PubMed Web of Science ®Google Scholar
• RuggieroLSDodsonTBFantasiaJAmerican Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 updateJ Oral Maxillofac Surg201472101938195625234529
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBröllJEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med199533322143714437477143
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar